The ad-tech platform integrates deeper pharma campaign insights as its stock slides.
Trade Desk expanded its integrations with healthcare data specialists Veeva Systems and IQVIA on 19 September 2026. The move allows pharmaceutical advertisers to access more granular campaign insights directly inside its advertising platform.
The operational push comes during a prolonged decline in the company's share price. Trade Desk shares are down 24.8% over the past 90 days, down 63.1% year-to-date, and have dropped 68.7% in total shareholder return over the past year.
The company remains profitable and generates positive net income, but its revenue growth has slowed amid tighter advertising budgets and rising digital advertising competition. Year-over-year revenue growth moderated from 235% in 2023 to 12.8% in 2025.
Share prices can rise and fall. Past performance does not guarantee future results. This article is news, not investment advice.
Newsletter
Markets in your inbox, weekly
LATAM-focused analysis, investing ideas, and the week in finance.
Keep reading